{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033464","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.563295+00:00","generated_at":"2026-06-04T13:18:12.959473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tempest reports FY2023 net loss $29.5M; positive Phase 1b/2 HCC data for TPST-1120","bullets":["Net loss $29.5M ($1.91/sh) vs $35.7M in 2022; cash $39.2M, runway into Q2 2025.","TPST-1120 triplet arm: 30% cORR vs 13.3% control; OS HR 0.59 favoring TPST-1120 in first-line HCC.","Plan to advance TPST-1120 into pivotal Phase 3 in HCC; TPST-1495 into Phase 2 FAP (pending NCI).","R&D expenses down to $17.5M from $22.5M, primarily due to lower CRO costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033464","json":"https://secwatch.observer/filing/0000950170-24-033464.json","markdown":"https://secwatch.observer/filing/0000950170-24-033464.md","text":"https://secwatch.observer/filing/0000950170-24-033464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/0000950170-24-033464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/tpst-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:18:12.959473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c279f8dd2fe28fbf208c0338e8210b42d268d70f","claim":"Tempest Therapeutics, Inc. reported financial results for year ended December 31, 2023.","evidence_excerpt":"On March 19, 2024, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/0000950170-24-033464-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}